CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer
Jiyang Xue1 ,* Ruixiang Li2 ,* Dingding Gao,2 Fenghua Chen,3 Hongjuan Xie1 1Department of Pharmacy, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai 201204, People’s Republic of China; 2Innovation Research Institute of Traditional Chinese Medicin...
Guardado en:
Autores principales: | Xue J, Li R, Gao D, Chen F, Xie H |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3298513a32ec4ace9a65bb7cd2881bc5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CXCR3 chemokine receptor ligands in sarcoidosis
por: N. M. Lazareva, et al.
Publicado: (2021) -
CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation
por: Ullah A, et al.
Publicado: (2019) -
Target engagement of the first-in-class CXCR7 antagonist ACT-1004-1239 following multiple-dose administration in mice and humans
por: Christine Huynh, et al.
Publicado: (2021) -
Met and Cxcr4 cooperate to protect skeletal muscle stem cells against inflammation-induced damage during regeneration
por: Ines Lahmann, et al.
Publicado: (2021) -
CXCL14 facilitates the growth and metastasis of ovarian carcinoma cells via activation of the Wnt/β-catenin signaling pathway
por: Li-Na Gao, et al.
Publicado: (2021)